[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, it is mentioned that chimeric antigen receptor (CAR)-T cell therapies have been approved for the treatment of B cell malignancies. Document [1] states that there are currently three FDA-approved products for the treatment of relapsed/refractory B-cell malignancies. Document [2] also mentions that CAR-T cells have two FDA-approved indications, including relapsed or refractory acute lymphoblastic leukemia in children and young adults, as well as large B cell lymphoma that is relapsed and/or refractory to two prior therapies. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]